替格瑞洛联合阿司匹林在携带CYP2C19功能缺失等位基因的急性缺血性卒中或短暂性脑缺血发作患者中的获益与风险时程:CHANCE-2随机临床试验的二次分析
这项CHANCE-2随机临床试验的二次分析纳入6412例携带CYP2C19功能缺失等位基因的急性轻型卒中或TIA患者,比较替格瑞洛联合阿司匹林与氯吡格雷联合阿司匹林。替格瑞洛联合阿司匹林降低主要缺血事件主要发生在第一周(绝对风险降低1.34%,95%CI 0.29至2.39),随后3周获益减弱但仍存在;任何出血的绝对增加在第一周为0.87%(95%CI 0.25至1.50),并在随后3周持续。
要点
- 替格瑞洛联合阿司匹林降低主要缺血事件主要见于第一周,绝对风险降低1.34%(95%CI 0.29至2.39)。
- 第二至第四周主要缺血事件绝对风险降低分别为0.11%、0.14%、0.04%,置信区间均跨0。
- 任何出血绝对增加第一周为0.87%(95%CI 0.25至1.50),第二周为1.21%(95%CI 0.75至1.68)。
核心结论
- 在携带CYP2C19功能缺失等位基因的轻型卒中或TIA患者中,替格瑞洛联合阿司匹林的获益主要出现在第一周,并在随后2周有额外小幅获益。
研究设计与样本
- CHANCE-2随机临床试验的二次分析,纳入中国202家医院2019年9月23日至2021年3月22日入组的40岁及以上急性轻型卒中或TIA且携带CYP2C19功能缺失等位基因的患者,随访90天。
- 共纳入CHANCE-2试验全部6412例患者,数据于2021年10月分析。
主要发现
- 替格瑞洛联合阿司匹林组3205例,氯吡格雷联合阿司匹林组3207例;中位(IQR)年龄65(57-71)岁,男性4242例(66%)。
- 主要缺血事件(缺血性卒中或非出血性死亡的复合终点)绝对风险降低:第一周1.34%(95%CI 0.29至2.39),第二周0.11%(95%CI -0.24至0.45),第三周0.14%(95%CI -0.11至0.38),第四周0.04%(95%CI -0.18至0.25)。
- 任何出血绝对增加:第一周0.87%(95%CI 0.25至1.50),第二周1.21%(95%CI 0.75至1.68),第三周0.33%(95%CI -0.05至0.72),第四周0.23%(95%CI -0.03至0.49)。
- 替格瑞洛联合阿司匹林组中重度出血风险持续较低。
关键数值与推荐
- 替格瑞洛用法:第1天180 mg,第2-90天90 mg每日两次;氯吡格雷用法:第1天300 mg,第2-90天75 mg每日一次;所有患者阿司匹林第1天75-300 mg,随后75 mg每日一次共21天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dual antiplatelet therapy (DAPT) with ticagrelor and aspirin has been found to be effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA) in individuals who carry CYP2C19 loss-of-function (LOF) alleles; however, uncertainties remain about the time course of benefit and risk with ticagrelor and aspirin in these patients. OBJECTIVE: To obtain time-course estimates of efficacy and risk with ticagrelor and aspirin after minor stroke or TIA in individuals with CYP2C19 LOF alleles. DESIGN, SETTING, AND PARTICIPANTS: The Ticagrelor or Clopidogrel With Aspirin in High-risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) randomized clinical trial enrolled patients 40 years and older from 202 hospitals in China with acute minor stroke or TIA who carried CYP2C19 LOF alleles between September 23, 2019, and March 22, 2021, and were followed up for 90 days. All 6412 patients enrolled in the CHANCE-2 trial were included in this secondary analysis. Data were analyzed in October 2021. INTERVENTIONS: Ticagrelor (180 mg on day 1 followed by 90 mg twice daily on days 2-90) or clopidogrel (300 mg on day 1 followed by 75 mg daily on days 2-90). All patients received aspirin (75-300 mg on day 1 followed by 75 mg daily for 21 days). MAIN OUTCOMES AND MEASURES: The efficacy outcome was major ischemic event, defined as the composite of ischemic stroke or nonhemorrhagic death. Safety outcomes included moderate to severe bleeding and any bleeding. RESULTS: A total of 6412 patients were included (3205 in the ticagrelor and aspirin group and 3207 in the clopidogrel and aspirin group). The median (IQR) age was 65 (57-71) years, and 4242 patients (66%) were men. The reduction of major ischemic events with ticagrelor and aspirin predominately occurred in the first week (absolute risk reduction, 1.34%; 95% CI, 0.29 to 2.39) and attenuated but remained in the next 3 weeks (absolute risk reduction in the second week, 0.11%; 95% CI, -0.24 to 0.45; absolute risk reduction in the third week, 0.14%; 95% CI, -0.11 to 0.38; absolute risk reduction in the fourth week, 0.04%; 95% CI, -0.18 to 0.25). The risk of moderate to severe bleeding was consistently low in the ticagrelor and aspirin group. The absolute increase in any bleeding seen in the first week (0.87%; 95% CI, 0.25 to 1.50) remained in the next 3 weeks (absolute increase in the second week, 1.21%; 95% CI, 0.75 to 1.68; absolute increase in the third week, 0.33%; 95% CI, -0.05 to 0.72; absolute increase in the fourth week, 0.23%; 95% CI, -0.03 to 0.49). CONCLUSION AND RELEVANCE: Among patients with minor stroke or TIA who carried CYP2C19 LOF alleles, benefit with ticagrelor and aspirin was present predominately in the first week, with additional small benefit accruing in the next 2 weeks.
引用
- Pan Y, Meng X, Jin A, et al. Time Course for Benefit and Risk With Ticagrelor and Aspirin in Individuals With Acute Ischemic Stroke or Transient Ischemic Attack Who Carry CYP2C19 Loss-of-Function Alleles: A Secondary Analysis of the CHANCE-2 Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35727586. doi:10.1001/jamaneurol.2022.1457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。